Related Experiment Videos
U.S. Government quality control program for Limulus amebocyte lysate and endotoxin
Progress in Clinical and Biological Research
|January 1, 1985
Summary
The U.S. requires licensed Limulus Amebocyte Lysate manufacturers to validate endotoxin test sensitivity using U.S. Standard Endotoxin. Lot release involves annual inspections and FDA potency testing for gelation and chromogenic assays.
Area of Science:
- Microbiology
- Biotechnology
- Regulatory Science
Background:
- The U.S. Government licenses multiple Limulus Amebocyte Lysate (LAL) manufacturers for endotoxin detection.
- Ensuring the sensitivity and potency of LAL test kits is critical for public health and pharmaceutical safety.
Purpose of the Study:
- To outline the regulatory requirements for LAL manufacturers in the United States.
- To describe the procedures for lot release and quality control of LAL products.
Main Methods:
- Manufacturers must validate lot sensitivity using the U.S. Standard Endotoxin, EC-5 (U.S. Pharmacopeia Endotoxin Standard Lot F).
- Annual inspections and submission of protocols with potency testing results are mandatory for licensed firms.
- The Food and Drug Administration (FDA) conducts potency testing on each LAL lot before market release.
Main Results:
- The study details the release criteria for both gelation and chromogenic LAL tests.
- Compliance with U.S. regulatory standards ensures the reliability of endotoxin detection.
Conclusions:
- Adherence to stringent U.S. regulatory guidelines, including standardized testing and FDA oversight, is essential for the quality and efficacy of Limulus Amebocyte Lysate products.
- The described procedures guarantee that LAL test kits meet required potency and sensitivity standards for endotoxin detection.